Boston Scientific (NYSE:BSX) Earns Outperform Rating from Royal Bank Of Canada

Key Points

• Royal Bank of Canada reiterated an Outperform rating on Boston Scientific with a $115 price target, implying roughly an 82.9% upside; the street consensus is a "Moderate Buy" with an average target near $104.36.
• Shares fell about 9.1% to $62.88 amid investor concerns over management's 2026 outlook, analyst price‑target cuts, legal/class‑action overhang and notable insider/institutional selling, even as the company posted a slight quarterly EPS beat ($0.80 vs. $0.78) and set FY‑2026 guidance of $3.430–$3.490.

Boston Scientific (NYSE:BSX - Get Free Report)'s stock had its "outperform" rating restated by Royal Bank Of Canada in a research note issued to investors on Monday,Benzinga reports. They currently have a $115.00 price objective on the medical equipment provider's stock. Royal Bank Of Canada's price target indicates a potential upside of 82.90% from the company's current price.

BSX has been the subject of several other reports. UBS Group decreased their price objective on shares of Boston Scientific from $120.00 to $105.00 and set a "buy" rating for the company in a report on Tuesday, March 17th. Canaccord Genuity Group cut their target price on shares of Boston Scientific from $112.00 to $109.00 and set a "buy" rating for the company in a research report on Tuesday, February 17th. Weiss Ratings cut shares of Boston Scientific from a "buy (b-)" rating to a "hold (c+)" rating in a report on Wednesday, February 4th. TD Cowen dropped their price objective on Boston Scientific from $115.00 to $100.00 and set a "buy" rating on the stock in a research note on Monday, February 2nd. Finally, Morgan Stanley cut their price objective on Boston Scientific from $130.00 to $118.00 and set an "overweight" rating for the company in a research report on Thursday, February 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $104.36.

Boston Scientific Stock Down 9.1%

Shares of NYSE:BSX traded down $6.29 on Monday, reaching $62.88. The company had a trading volume of 25,709,020 shares, compared to its average volume of 15,433,893. The stock has a market capitalization of $93.45 billion, a P/E ratio of 32.41, a P/E/G ratio of 1.07 and a beta of 0.69. The stock has a 50-day moving average price of $77.45 and a 200 day moving average price of $90.61. Boston Scientific has a twelve month low of $61.25 and a twelve month high of $109.50. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts' consensus estimates of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. During the same period last year, the business earned $0.70 EPS. The firm's revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, equities analysts expect that Boston Scientific will post 2.85 EPS for the current year.

Insider Activity

In other news, CEO Michael F. Mahoney sold 160,901 shares of the company's stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares of the company's stock, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.34% of the company's stock.

Hedge Funds Weigh In On Boston Scientific

Several large investors have recently added to or reduced their stakes in BSX. Gerber Kawasaki Wealth & Investment Management increased its position in shares of Boston Scientific by 3.8% during the second quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider's stock valued at $291,000 after purchasing an additional 99 shares during the period. Crown Wealth Group LLC lifted its position in Boston Scientific by 4.7% in the third quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider's stock worth $218,000 after purchasing an additional 100 shares during the period. Claret Asset Management Corp boosted its stake in Boston Scientific by 4.4% during the third quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider's stock worth $234,000 after buying an additional 102 shares in the last quarter. Cary Street Partners Investment Advisory LLC increased its holdings in Boston Scientific by 5.1% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider's stock valued at $206,000 after buying an additional 103 shares during the period. Finally, Scotia Capital Inc. increased its holdings in Boston Scientific by 0.7% in the 2nd quarter. Scotia Capital Inc. now owns 15,093 shares of the medical equipment provider's stock valued at $1,621,000 after buying an additional 104 shares during the period. Institutional investors and hedge funds own 89.07% of the company's stock.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Late‑breaking clinical wins — the HI‑PEITHO results showed the EKOS™ Endovascular System superior to standard of care for intermediate‑risk pulmonary embolism, supporting adoption and future revenue upside. HI-PEITHO trial demonstrates Boston Scientific EKOS
• Positive Sentiment: CHAMPION‑AF: the WATCHMAN FLX trial met primary and secondary endpoints versus NOACs, reinforcing the device’s long‑term market opportunity in LAAC. CHAMPION-AF study of the WATCHMAN FLX
• Positive Sentiment: Some sell‑side support remains: Needham reaffirmed a Buy with a $97 PT and other analysts continue to rate BSX favorably, leaving upside if execution steadies. Needham rating report
• Neutral Sentiment: Corporate calendar: BSX scheduled a Q1 2026 earnings/webcast (April 22) — investors will watch guidance, procedure volumes, and margin commentary for confirmation of management’s 2026 outlook. Q1 2026 conference call announcement
• Negative Sentiment: Guidance and repricing: market reaction appears driven by management’s 2026 outlook implying slower growth vs. an unusually strong prior year and commentary about mix/operational headwinds — investors are revising earnings multiples. QuiverQuant analysis of BSX slide
• Negative Sentiment: Legal overhang: multiple firms have filed or pushed class‑action notices and investor‑solicitation alerts related to a July 2025–Feb 2026 class period, which increases headline risk and can suppress the stock until resolved. RGRD Law investor alert on class action
• Negative Sentiment: Capital‑markets pressure: notable institutional trimming (large reported reductions by several asset managers) and clustered insider sell activity increase supply risk and signal near‑term cautious positioning by big holders. QuiverQuant institutional & insider activity
• Negative Sentiment: Analyst price‑target trims: Goldman Sachs and others lowered targets (e.g., GS to $93; Raymond James cut its PT to $88), which can mechanically pressure the stock and reinforce downward momentum. Goldman Sachs cuts BSX price target

About Boston Scientific

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.